Arcus Biosciences Q1 2025 Update
Ticker: RCUS · Form: 10-Q · Filed: May 6, 2025 · CIK: 1724521
Sentiment: neutral
Topics: 10-Q, financials, revenue, collaboration
TL;DR
Arcus Bio Q1 2025: Revenue from collaborations detailed. Check financials.
AI Summary
Arcus Biosciences, Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's revenue streams include License and Development Services Revenue and Other Collaboration Revenue. Specific financial figures for these revenue categories for Q1 2025 and Q1 2024 are detailed within the filing.
Why It Matters
This filing provides insight into Arcus Biosciences' financial performance and revenue generation from its collaborations in the first quarter of 2025, which can impact investor outlook and strategic decisions.
Risk Assessment
Risk Level: medium — The company operates in the highly competitive and regulated pharmaceutical industry, facing risks related to drug development, clinical trials, and market adoption.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of 2025 financial performance)
- Q1 2024 — Prior Period (Comparison for Q1 2025 revenue)
Key Players & Entities
- Arcus Biosciences, Inc. (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250506 (date) — Filing Date
- LicenseAndDevelopmentServicesRevenueMember (dollar_amount) — Revenue Category
- OtherCollaborationRevenueMember (dollar_amount) — Revenue Category
FAQ
What were the specific dollar amounts for License and Development Services Revenue in Q1 2025?
The filing details License and Development Services Revenue for Q1 2025, but specific dollar amounts are not provided in this excerpt.
How does the Other Collaboration Revenue in Q1 2025 compare to Q1 2024?
The filing indicates that Other Collaboration Revenue for Q1 2025 and Q1 2024 are reported, allowing for comparison, though specific figures are not in this snippet.
What is the primary business of Arcus Biosciences, Inc. according to the SIC code?
Arcus Biosciences, Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted on May 6, 2025.
What is the fiscal year end for Arcus Biosciences, Inc.?
The fiscal year end for Arcus Biosciences, Inc. is December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding Arcus Biosciences, Inc. (RCUS).